TWI882032B - Tyk2假激酶配位體 - Google Patents

Tyk2假激酶配位體 Download PDF

Info

Publication number
TWI882032B
TWI882032B TW109138709A TW109138709A TWI882032B TW I882032 B TWI882032 B TW I882032B TW 109138709 A TW109138709 A TW 109138709A TW 109138709 A TW109138709 A TW 109138709A TW I882032 B TWI882032 B TW I882032B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
solvate
Prior art date
Application number
TW109138709A
Other languages
English (en)
Chinese (zh)
Other versions
TW202128698A (zh
Inventor
拉朱 莫漢
約翰 尼斯
傑森 哈里斯
沈東 袁
Original Assignee
美商凡帝克斯生物科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凡帝克斯生物科學公司 filed Critical 美商凡帝克斯生物科學公司
Publication of TW202128698A publication Critical patent/TW202128698A/zh
Application granted granted Critical
Publication of TWI882032B publication Critical patent/TWI882032B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
TW109138709A 2019-11-08 2020-11-05 Tyk2假激酶配位體 TWI882032B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962933179P 2019-11-08 2019-11-08
US62/933,179 2019-11-08
US202063046514P 2020-06-30 2020-06-30
US63/046,514 2020-06-30

Publications (2)

Publication Number Publication Date
TW202128698A TW202128698A (zh) 2021-08-01
TWI882032B true TWI882032B (zh) 2025-05-01

Family

ID=75846491

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109138709A TWI882032B (zh) 2019-11-08 2020-11-05 Tyk2假激酶配位體

Country Status (17)

Country Link
US (2) US11753411B2 (enExample)
EP (1) EP4054581A4 (enExample)
JP (1) JP7635228B2 (enExample)
KR (1) KR102938141B1 (enExample)
CN (1) CN114929226B (enExample)
AU (1) AU2020378345A1 (enExample)
BR (1) BR112022008821A2 (enExample)
CA (1) CA3160637A1 (enExample)
CL (1) CL2022001178A1 (enExample)
CO (1) CO2022007814A2 (enExample)
GE (1) GEP20257840B (enExample)
IL (1) IL292785B2 (enExample)
MX (1) MX2022005563A (enExample)
PH (1) PH12022551105A1 (enExample)
TW (1) TWI882032B (enExample)
UA (1) UA129894C2 (enExample)
WO (1) WO2021092246A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
MX2021009555A (es) * 2019-02-07 2021-10-13 Ventyx Biosciences Inc Ligandos de pseudocinasa tyk2.
IL286248B2 (en) * 2019-03-11 2025-12-01 Alumis Inc Tyk2 inhibitors and uses thereof
EA202192625A1 (ru) 2019-03-26 2022-03-21 Вентикс Байосайенсес, Инк. Лиганды псевдокиназы tyk2
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2024011136A1 (en) * 2022-07-06 2024-01-11 Ventyx Biosciences, Inc. Crystalline forms of a tyk2 inhibitor
EP4649082A1 (en) * 2023-01-13 2025-11-19 Ventyx Biosciences, Inc. Preparation of a tyk2 inhibitor
CN117247389A (zh) * 2023-09-18 2023-12-19 南京友怡医药科技有限公司 一种靶向药物化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114739A1 (en) * 2009-04-09 2012-05-10 Yongqi Deng PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
TW201920178A (zh) * 2017-07-28 2019-06-01 美商林伯士拉克許米公司 Tyk2抑制劑及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050115252A (ko) 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
TWI868528B (zh) 2017-03-08 2025-01-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑之生產方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20200360381A1 (en) 2017-05-15 2020-11-19 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
ES2938751T3 (es) 2018-09-10 2023-04-14 Lilly Co Eli Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico
CA3115088A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
MX2021009555A (es) 2019-02-07 2021-10-13 Ventyx Biosciences Inc Ligandos de pseudocinasa tyk2.
IL286248B2 (en) 2019-03-11 2025-12-01 Alumis Inc Tyk2 inhibitors and uses thereof
EA202192625A1 (ru) 2019-03-26 2022-03-21 Вентикс Байосайенсес, Инк. Лиганды псевдокиназы tyk2
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114739A1 (en) * 2009-04-09 2012-05-10 Yongqi Deng PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
TW201920178A (zh) * 2017-07-28 2019-06-01 美商林伯士拉克許米公司 Tyk2抑制劑及其用途

Also Published As

Publication number Publication date
CN114929226A (zh) 2022-08-19
CL2022001178A1 (es) 2023-02-03
TW202128698A (zh) 2021-08-01
US11753411B2 (en) 2023-09-12
UA129894C2 (uk) 2025-09-03
EP4054581A1 (en) 2022-09-14
KR102938141B1 (ko) 2026-03-11
IL292785B2 (en) 2025-09-01
US20230348478A1 (en) 2023-11-02
IL292785B1 (en) 2025-05-01
CN114929226B (zh) 2024-09-27
MX2022005563A (es) 2022-08-19
CO2022007814A2 (es) 2022-09-09
CA3160637A1 (en) 2021-05-14
WO2021092246A1 (en) 2021-05-14
GEP20257840B (en) 2025-12-25
JP2022553841A (ja) 2022-12-26
KR20220107194A (ko) 2022-08-02
PH12022551105A1 (en) 2023-11-20
JP7635228B2 (ja) 2025-02-25
EP4054581A4 (en) 2023-11-22
US20210139486A1 (en) 2021-05-13
AU2020378345A1 (en) 2022-06-02
IL292785A (en) 2022-07-01
BR112022008821A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
KR102938141B1 (ko) Tyk2 슈도키나제 리간드
CN113874021B (zh) Tyk2假激酶配体
JP2022519696A (ja) Ｔｙｋ２偽キナーゼリガンド
TWI865525B (zh) Jak抑制劑
JP2022549435A (ja) Ｊａｋ阻害剤
JP2022544174A (ja) Ｊａｋ阻害剤
HK40080028B (zh) Tyk2假激酶配体
EA047570B1 (ru) Лиганды псевдокиназы tyk2
HK40080028A (en) Tyk2 pseudokinase ligands
HK40066192B (zh) Tyk2假激酶配体
HK40066192A (zh) Tyk2假激酶配体
HK40080624A (en) Jak inhibitors
HK40072097A (en) Jak inhibitors
HK40064378A (en) Tyk2 pseudokinase ligands